Abbvie Inc.

Other

Abbott Research B.v.

Wei Liu

Sandeep Dutta

Walid M Awni

Barry M Bernstein

Sven Mensing

Thomas J Podsadecki

Rajeev M Menon

Andrea Best

Jerry A Hall

Chih-Wei Lin

John Powell

Duncan Casson

Mark Maginn

Andrew L Campbell

Tianli Wang

The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the treatment comprises administering at least two direct acting antiviral agents to a subject with HCV infection, wherein the treatment lasts for 12 weeks and does not include administration of either interferon or ribavirin, and said at least two direct acting antiviral agents comprise (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.

Methods for treating HCV

Method for treating HCV

The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.

Antibodies against nerve growth factor (NGF) with enhanced in vivo stability

Growing community of inventors

Mundelein, IL, United States of America

Wei Liu